Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia

R eferences

• Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005 Dec;128(6):3854–3862.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1;46(Suppl S5):S378–85.
   PubMedGoogle Scholar
• Aliberti S, Reyes LF, Faverio P, et al. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016 Dec;16(12):1364–1376.
   PubMed Web of Science ®Google Scholar
• He H, Wunderink RG. Staphylococcus aureus Pneumonia in the Community. Semin Respir Crit Care Med. 2020 Aug;41(4):470–479.
   PubMedGoogle Scholar
• Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016 Aug 1;63(3):300–309.
   PubMed Web of Science ®Google Scholar
• De La Calle C, Morata L, Cobos-Trigueros N, et al. Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):497–502.
   PubMed Web of Science ®Google Scholar
• Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999 Nov;29(5):1171–1177.
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45–e67.
   PubMed Web of Science ®Google Scholar
• Montravers P, Harpan A, Guivarch E. Current and future considerations for the treatment of hospital-acquired pneumonia. Adv Ther. 2016 Feb;33(2):151–166.
   PubMed Web of Science ®Google Scholar
• Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021 Jan;217:107663.
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017 Sep;50(3):1700582 .
   Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Carnelutti A, Castaldo N, et al. Important new therapies for methicillin-resistant Staphylococcus aureus. Expert Opin Pharmacother. 2019 Dec;20(18):2317–2334.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Del Puente F, Magnasco L, et al. Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin Investig Drugs. 2020 May;29(5):495–506.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020 May;18(5):286–298.
   PubMed Web of Science ®Google Scholar
• Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021;Dec;12(1):547–569.
   PubMed Web of Science ®Google Scholar
• Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019 Apr;17(4):203–218.
   PubMed Web of Science ®Google Scholar
• Peacock SJ, Paterson GK. Mechanisms of Methicillin Resistance in Staphylococcus aureus. Annu Rev Biochem. 2015;84(1):577–601.
   PubMedGoogle Scholar
• Bassetti M, Russo A, Carnelutti A, et al. Emerging drugs for treating methicillin-resistant Staphylococcus aureus. Expert Opin Emerg Drugs. 2019 Sep;24(3):191–204.
   PubMed Web of Science ®Google Scholar
• Desai R, Pannaraj PS, Agopian J, et al. Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites. Am J Infect Control. 2011 Apr;39(3):219–225.
   PubMed Web of Science ®Google Scholar
• Von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med. 2001 Jan 4;344(1):11–16.
   PubMed Web of Science ®Google Scholar
• Paling FP, Wolkewitz M, Bode LGM, et al. Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia. Clin Microbiol Infect. 2017 Jan;23(1):49e9–49 e14.
   Web of Science ®Google Scholar
• Tilahun B, Faust AC, McCorstin P, et al. Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus. Am J Crit Care. 2015 Jan;24(1):8–12.
   PubMed Web of Science ®Google Scholar
• Kreienbuehl L, Charbonney E, Eggimann P. Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports. Ann Intensive Care. 2011 Dec 22;1(1):52.
   PubMedGoogle Scholar
• Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013 Oct;11(10):1041–1051.
   PubMed Web of Science ®Google Scholar
• Saeed K, Gould I, Esposito S, et al. Panton-Valentine leukocidin-positive Staphylococcus aureus: a position statement from the International Society of Chemotherapy. Int J Antimicrob Agents. 2018 Jan;51(1):16–25.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents. 2009 Jul;34(Suppl 1):S15–9.
   PubMedGoogle Scholar
• Choo EJ. Community-Associated Methicillin-Resistant Staphylococcus aureus in Nosocomial Infections. Infect Chemother. 2017 Jun;49(2):158–159.
   PubMed Web of Science ®Google Scholar
• Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005 Feb 15;40(4):562–573.
   PubMed Web of Science ®Google Scholar
• Kong EF, Johnson JK, Jabra-Rizk MA. Community-Associated Methicillin-Resistant Staphylococcus aureus: an enemy amidst Us. PLoS Pathog. 2016 Oct;12(10):e1005837.
   PubMed Web of Science ®Google Scholar
• Valsesia G, Rossi M, Bertschy S, et al. Emergence of SCCmec type IV and SCCmec type V methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leukocidin genes in a large academic teaching hospital in central Switzerland: external invaders or persisting circulators? J Clin Microbiol. 2010 Mar;48(3):720–727.
   PubMed Web of Science ®Google Scholar
• Sun K, Yajjala VK, Bauer C, et al. Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza S. aureus pneumonia. J Exp Med. 2016 Aug 22;213(9):1851–1864.
   PubMed Web of Science ®Google Scholar
• Jacquot A, Luyt CE, Kimmoun A, et al. Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine leucocidin positive Staphylococcus aureus in intensive care units: a retrospective nationwide study. Intensive Care Med. 2019 Sep;45(9):1312–1314.
   PubMed Web of Science ®Google Scholar
• Baskaran V, Lawrence H, Lansbury LE, et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. J Med Microbiol. 2021 Apr;70(4). doi:https://doi.org/10.1099/jmm.0.001350.
   Google Scholar
• Catano-Correa JC, Cardona-Arias JA, Porras Mancilla JP, et al. Bacterial superinfection in adults with COVID-19 hospitalized in two clinics in Medellin-Colombia, 2020. PLoS One. 2021;16(7):e0254671.
   PubMed Web of Science ®Google Scholar
• Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020 Sep 7;10(1):119.
   PubMed Web of Science ®Google Scholar
• De Pascale G, De Maio F, Carelli S, et al. Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. Crit Care. 2021 Jun 7;25(1):197.
   PubMed Web of Science ®Google Scholar
• Fontana C, Favaro M, Minelli S, et al. Co-infections observed in SARS-CoV-2 positive patients using a rapid diagnostic test. Sci Rep. 2021 Aug 11;11(1):16355.
   PubMed Web of Science ®Google Scholar
• Foschi C, Zignoli A, Gaibani P, et al. Respiratory bacterial co-infections in intensive care unit-hospitalized COVID-19 patients: conventional culture vs biofire filmarray pneumonia plus panel. J Microbiol Methods. 2021 Jul;186:106259.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021 Jan;27(1):83–88.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Battaglini D, Enrile EM, et al. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. J Clin Med. 2021 Feb 3;10(4):555.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Russo C, Martini V, et al. Use of ceftaroline in hospitalized patients with and without COVID-19: a descriptive cross-sectional study. Antibiotics (Basel). 2021 Jun 23;10(7). DOI:https://doi.org/10.3390/antibiotics10070763.
   Google Scholar
• Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest. 2021 Aug;160(2):454–465.
   PubMed Web of Science ®Google Scholar
• Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020 Oct;26(10):1395–1399.
   PubMed Web of Science ®Google Scholar
• Kolenda C, Ranc AG, Boisset S, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and biofire, filmarray pneumonia panel plus assay. Open Forum Infect Dis. 2020 Nov;7(11):ofaa484.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020 Sep 22;9(1):153.
   PubMed Web of Science ®Google Scholar
• Risa E, Roach D, Budak JZ, et al. Characterization of secondary bacterial infections and antibiotic use in mechanically ventilated patients with COVID-19 induced acute respiratory distress syndrome. J Intensive Care Med. 2021;10:8850666211021745.
   Google Scholar
• Ruiz-Bastian M, Falces-Romero I, Ramos-Ramos JC, et al. Bacterial co-infections in COVID-19 pneumonia in a tertiary care hospital: surfing the first wave. Diagn Microbiol Infect Dis. 2021 Jul 3;101(3):115477.
   PubMed Web of Science ®Google Scholar
• Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021 Aug;2(8):e354–e365.
   PubMedGoogle Scholar
• Senok A, Alfaresi M, Khansaheb H, et al. Coinfections in patients hospitalized with COVID-19: a descriptive study from the United Arab Emirates. Infect Drug Resist. 2021;14:2289–2296.
   PubMed Web of Science ®Google Scholar
• Singh V, Upadhyay P, Reddy J, et al. SARS-CoV-2 respiratory co-infections: incidence of viral and bacterial co-pathogens. Int J Infect Dis. 2021 Apr;105:617–620.
   PubMed Web of Science ®Google Scholar
• Soto A, Quinones-Laveriano DM, Valdivia F, et al. Detection of viral and bacterial respiratory pathogens identified by molecular methods in COVID-19 hospitalized patients and its impact on mortality and unfavorable outcomes. Infect Drug Resist. 2021;14:2795–2807.
   PubMed Web of Science ®Google Scholar
• Tang H, Zhao Z, Zhang X, et al. Analysis of pathogens and risk factors of secondary pulmonary infection in patients with COVID-19. Microb Pathog. 2021 Jul;156:104903.
   PubMed Web of Science ®Google Scholar
• Yang S, Hua M, Liu X, et al. Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. Microbes Infect. 2021 May-Jun;23(4–5):104806.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Bruzzi P, et al. Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021;10 :1837–1885.
   PubMed Web of Science ®Google Scholar
• Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011 Nov;45(11):1384–1398.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Castanheira M, Mendes RE, et al. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis. 2012 Sep;55(Suppl 3):S206–14.
   PubMedGoogle Scholar
• File TM Jr., Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66(Suppl 3):iii19–32.
   PubMed Web of Science ®Google Scholar
• Low DE, File TM Jr., Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66(Suppl 3):iii33–44.
   PubMed Web of Science ®Google Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015 Feb;15(2):161–171.
   PubMed Web of Science ®Google Scholar
• Ramani A, Udeani G, Evans J, et al. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother. 2014 Aug;26(4):229–234.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Aliberti S, Gramegna A, et al. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respir Res. 2018 Oct 23;19(1):205.
   PubMedGoogle Scholar
• Bassetti M, Russo A, Cilloniz C, et al. Ceftaroline for severe community-acquired pneumonia: a real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020 Apr;55(4):105921.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Castaldo N, et al. The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf. 2019 Aug;18(8):635–650.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Labate L, Vena A, et al. Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis. 2021 Apr 1;34(2):109–117.
   PubMed Web of Science ®Google Scholar
• Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016 Jul;71(7):2010–2013.
   PubMed Web of Science ®Google Scholar
• LaVie KW, Anderson SW, O’Neal HR Jr., et al. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2016 Jan;60(1):264–269.
   PubMed Web of Science ®Google Scholar
• Varada NL, Sakoulas G, Lei LR, et al. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015 Jun;35(6):608–612.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, De Rosa FG, Del Bono V, et al. Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther. 2019 Sep;17(9):689–698.
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001 Mar;45(3):825–836.
   PubMed Web of Science ®Google Scholar
• Lovering AL, Gretes MC, Safadi SS, et al. Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J Biol Chem. 2012 Sep 14;287(38):32096–32102.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012 Mar;39(3):240–246.
   PubMed Web of Science ®Google Scholar
• Crapis M, Venturini S, Della Siega P, et al. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm? J Chemother. 2021 May;33(3):174–179.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Mazza MC, et al. Real-life experience with ceftobiprole in a tertiary-care hospital. J Glob Antimicrob Resist. 2020 Sep;22:386–390.
   PubMed Web of Science ®Google Scholar
• Oliva A, Savellon G, Cancelli F, et al. Real-life experience in the use of ceftobiprole for the treatment of nosocomial pneumonia: a case series. J Glob Antimicrob Resist. 2021 May;23(26):52–54.
   Google Scholar
• Zhanel GG, Kosar J, Baxter M, et al. Real-life experience with ceftobiprole in Canada: results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry. J Glob Antimicrob Resist. 2021 Mar;24:335–339.
   PubMed Web of Science ®Google Scholar
• Ltd BM. Public assessment report, Zevtera 500mg powder for concentrate for solution for infusion. Medicines and Healthcare Products Regulatory Agency.
   Google Scholar
• Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, et al. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2012 Aug;67(8):1961–1967.
   PubMed Web of Science ®Google Scholar
• Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect. 2001;7(Suppl 4):75–82.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat. 2014 Apr;17(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1121–1128.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Klompas M, Haynatzki G, et al. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open. 2013 Oct 14;3(10):e003912.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010 Sep;38(9):1802–1808.
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021 Mar;24:98–105.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zou Y, Xie J, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015 Jan;71(1):107–115.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012 Mar 1;54(5):621–629.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001 Feb 1;32(3):402–412.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003 Mar;25(3):980–992.
   PubMed Web of Science ®Google Scholar
• Caffrey AR, Morrill HJ, Puzniak LA, et al. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2014 May;34(5):473–480.
   PubMed Web of Science ®Google Scholar
• Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014 Jun 10;18(3):R118.
   PubMed Web of Science ®Google Scholar
• Takada H, Hifumi T, Nishimoto N, et al. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: a retrospective cohort analysis: effectiveness of linezolid in the elderly. Am J Emerg Med. 2017 Feb;35(2):245–248.
   PubMed Web of Science ®Google Scholar
• Tong MC, Wisniewski CS, Wolf B, et al. Comparison of linezolid and vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: institutional implications. Pharmacotherapy. 2016 Jul;36(7):731–739.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003 Jun;47(6):1824–1831.
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006 Jan 1;42(1):66–72.
   PubMed Web of Science ®Google Scholar
• Ferry T, Ponceau B, Simon M, et al. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection. 2005 Jun;33(3):151–154.
   PubMed Web of Science ®Google Scholar
• Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):491–498.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Rivera A, et al. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrob Agents Chemother. 2013 Dec;57(12):5901–5911.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Roquilly A, Croce M, et al. A Phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia. Clin Infect Dis. 2021 Aug 2;73(3):e710–e718.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Della Siega P, Pecori D, et al. Delafloxacin for the treatment of respiratory and skin infections. Expert Opin Investig Drugs. 2015 Mar;24(3):433–442.
   PubMed Web of Science ®Google Scholar
• Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother. 2021 Aug;4:1–8.
   Google Scholar
• Saravolatz LD, Pawlak JM, Wegner C. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2020 Sep 1;75(9):2605–2608.
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Salata RA, Alvarez-Sala R, et al. A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2020 Jan;7(1): ofz514. doi:https://doi.org/10.1093/ofid/ofz514.
   Google Scholar
• Lodise T, Corey R, Hooper D, et al. Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018 Oct;5(10): ofy220. doi:https://doi.org/10.1093/ofid/ofy220.
   Google Scholar
• O’Riordan W, McManus A, Teras J, et al. a comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a Phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018 Aug 16;67(5):657–666.
   PubMed Web of Science ®Google Scholar
• Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017 Dec 1;72(12):3471–3480.
   PubMed Web of Science ®Google Scholar
• Dawe RS, Ferguson J, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci. 2018 Jun 13;17(6):773–780.
   PubMed Web of Science ®Google Scholar
• Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59(6):3469–3473.
   PubMed Web of Science ®Google Scholar
• Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016 Mar;71(3):821–829.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015 Jan;30:67–73.
   PubMed Web of Science ®Google Scholar
• Sader HS, Biedenbach DJ, Paukner S, et al. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012 Mar;56(3):1619–1623.
   PubMed Web of Science ®Google Scholar
• Sader HS, Paukner S, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012 May;67(5):1170–1175.
   PubMed Web of Science ®Google Scholar
• Alexander E, Goldberg L, Das AF, et al. Oral Lefamulin vs Moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019 Nov 5;322(17):1661–1671.
   PubMed Web of Science ®Google Scholar
• File TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis. 2019 Nov 13;69(11):1856–1867.
   PubMed Web of Science ®Google Scholar
• Eraikhuemen N, Julien D, Kelly A, et al. Treatment of community-acquired pneumonia: a focus on lefamulin. Infect Dis Ther. 2021 Mar;10(1):149–163.
   PubMed Web of Science ®Google Scholar
• Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127–1135.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Rhomberg PR, et al. Surveillance of Omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011. Antimicrob Agents Chemother. 2017 May;61(5). doi:https://doi.org/10.1128/AAC.00018-17.
   Google Scholar
• European Medicines Agency (EMA). Withdrawal assessment report. Nuzyra (omadacycline tosylate). Procedure No. EMEA/H/C/4715. [cited 2021 Aug 24]. Available from: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nuzyra_en.pdf
   Google Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019 Feb 7;380(6):517–527.
   PubMed Web of Science ®Google Scholar
• Bodi M, Ardanuy C, Rello J. Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Crit Care Med. 2001 Apr;29(4 Suppl):N82–6.
   PubMed Web of Science ®Google Scholar
• Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1545–1549.
   PubMed Web of Science ®Google Scholar
• Brown NM, Goodman AL, Horner C, et al. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist. 2021 Mar;3(1):dlaa114.
   PubMedGoogle Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006 Oct 23;166(19):2138–2144.
   PubMedGoogle Scholar
• Mukhopadhyay J. Teicoplanin for treating MRSA pneumonia. BMJ. 2014 Mar;25(348):g2317.
   Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan 1;52(1):31–40.
   PubMed Web of Science ®Google Scholar
• Hong J, Ensom MHH, Lau TTY. what is the evidence for Co-trimoxazole, clindamycin, doxycycline, and minocycline in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia? Ann Pharmacother. 2019 Nov;53(11):1153–1161.
   PubMed Web of Science ®Google Scholar
• Harbarth S, Von Dach E, Pagani L, et al. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother. 2015 Jan;70(1):264–272.
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015 May;14(350):h2219.
   Google Scholar
• Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010 Jan;38(1):175–180.
   PubMed Web of Science ®Google Scholar
• Ramsey KM, Mazer MA. Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor. Crit Care Med. 2010 Jan;38(1):326–327.
   PubMed Web of Science ®Google Scholar
• Tremblay S, Lau TT, Ensom MH. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? Ann Pharmacother. 2013 Jul-Aug;47(7–8):1045–1054.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Quofenix. Summary of product characteristics. [cited 2021 Aug 25. Available from: https://www.ema.europa.eu/en/documents/product-information/quofenix-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Xenleta. Summary of product characteristics. [Cited 2021 Aug 25. Available from: https://www.ema.europa.eu/en/documents/product-information/xenleta-epar-product-information_en.pdf
   Google Scholar
• Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis. 1997 May;16(5):385–388.
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993 Feb;37(2):281–286.
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2006 Apr;26(4):539–550.
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006 Oct;130(4):947–955.
   PubMed Web of Science ®Google Scholar
• Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes. 2016 Sep 29;9(1):455.
   PubMedGoogle Scholar
• Rybak MJ, Le J, Lodise TP, et al. therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system pharmacists, the infectious diseases Society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Clin Infect Dis. 2020 Sep 12;71(6):1361–1364.
   PubMed Web of Science ®Google Scholar